SCHEMBL13278317

SCHEMBL13278317

Cc1ccc(C)c(-c2ccc3c(c2)CCCO3)c1C=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.44
ERN1 O75460 4/20 0.44
CREBBP Q92793 2/20 0.42
FABP4 P15090 2/20 0.41
DYRK1A Q13627 3/20 0.40
CTNNB1 P35222 2/20 0.40
WNT3A P56704 2/20 0.40
CLK1 P49759 1/20 0.40
DYRK1B Q9Y463 1/20 0.40
RIPK1 Q13546 1/20 0.39
PKLR P30613 1/20 0.38
FABP3 P05413 1/20 0.38
TRIM24 O15164 1/20 0.37
BRD1 O95696 1/20 0.37
BRPF1 P55201 1/20 0.37
HTR7 P34969 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27915696 0.80 HTR7 (0.53) NOTUMFABP4DYRK1ACTNNB1WNT3A
SCHEMBL16000215 0.79 NOTUM (0.41) NOTUMERN1CREBBPFABP4DYRK1A
SCHEMBL13278316 0.75 PIK3CD (0.35) ERN1CREBBPFABP4
SCHEMBL15996975 0.74 ERN1 (0.37) NOTUMERN1CREBBPFABP4CTNNB1
SCHEMBL14577277 0.74 ERN1 (0.40) NOTUMERN1CREBBPFABP4DYRK1A
SCHEMBL13193610 0.74 NOTUM (0.43) NOTUMERN1DYRK1ACTNNB1WNT3A
SCHEMBL14577395 0.74 NOTUM (0.41) NOTUMERN1CREBBPDYRK1ACLK1
SCHEMBL13465329 0.73 NOTUM (0.39) NOTUMCREBBPFABP4DYRK1ACTNNB1
SCHEMBL17788081 0.72 CTNNB1 (0.43) NOTUMERN1CREBBPFABP4CTNNB1
SCHEMBL16574214 0.72 NOTUM (0.50) NOTUMERN1DYRK1ACTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2697213-B1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES HIVIH (FR) 2018-12-12 EP disclosed
EP-3016714-B1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES HIVIH (FR) 2018-09-19 EP disclosed
US-9994509-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses HIVIH (FR) 2018-06-12 US disclosed
US-9994509-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses HIVIH (FR) 2018-06-12 US disclosed
US-9994509-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses HIVIH (FR) 2018-06-12 US disclosed
US-9604900-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-03-28 US disclosed
US-9604900-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-03-28 US disclosed
US-9604900-B2 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2017-03-28 US disclosed
US-20160152543-A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-06-02 US disclosed
US-20160152543-A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-06-02 US disclosed
US-20160152543-A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses LABORATOIRE BIODIM (FR) 2016-06-02 US disclosed
EP-3016714-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2016-05-11 EP disclosed
WO-2015001125-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2015-01-08 WO disclosed
EP-2697213-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2014-02-19 EP disclosed
US-20140031338-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2014-01-30 US disclosed
US-20140031338-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2014-01-30 US disclosed
US-20140031338-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2014-01-30 US disclosed
WO-2012140243-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES LABORATOIRE BIODIM (FR) 2012-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031338-A1 INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES POLRMT, MAVS, EIF2AK2 NOTUM 2638/4885ERN1 199/4885CREBBP 1028/4885
US-20160152543-A1 Inhibitors of viral replication, their process of preparation and their therapeutical uses POLRMT, MAVS, EIF2AK2 NOTUM 2638/4885ERN1 199/4885CREBBP 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.